Skip to main content

Table 3 Univariate and multivariate analysis of risk factors for overall survival

From: Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study

Variables

Overall survival

 

Univariate analysis

Multivariate analysis

 

HR

95%CI

p

HR

95%CI

p

Age (years), </≥60

1.185

1.305–2.129

0.747

   

Sex, (male/female)

0.583

0.392–2.470

0.274

   

BMI, (kg/m2), </≥25

1.191

0.726–1.103

0.125

   

ECOG (0/1)

1.182

0.943–2.734

0.282

   

Hepatitis B, (yes/no)

1.688

0.769–2.650

0.511

   

Hepatitis C, (yes/no)

1.352

0.144–2.013

0.206

   

AFP (ng/ml), </≥400

1.566

0.072–2.317

0.114

   

Child-Pugh (A/B)

2.403

2.500–8.434

0.005

2.633

1.391–9.648

0.001

BCLC (B/C)

1.390

0.651–2.591

0.171

   

Liver cirrhosis (yes/no)

1.772

0.785–3.647

0.663

   

PD-L1 expression

1.473

0.860–3.429

0.052

   

Tumor thrombus

      

Absent

      

Branch of portal vein

1.583

0.303–4.752

0.545

   

Main portal vein

1.276

0.295–6.298

0.901

   

Extrahepatic metastasis (yes/no)

1.292

0.747–3.842

0.118

   

Number of metastatic sites (< 3/≥3)

2.104

1.360–4.476

0.007

2.193

1.187–4.366

0.002

Treatment (PLH/PL)

2.499

1.726–4.902

0.005

3.649

1.592–6.074

0.001

  1. PLH pembrolizumab plus lenvatinib plus hepatic arterial infusion chemotherapy; PL pembrolizumab plus lenvatinib; BMI body mass index; ECOG Eastern Collaborative Oncology Group; AFP alpha fetoprotein; BCLC Barcelona clinic liver cancer; PD-L1 programmed cell death ligand-1